Clinical Trials Logo

Fistulizing Crohn's Disease clinical trials

View clinical trials related to Fistulizing Crohn's Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03452501 Completed - Ulcerative Colitis Clinical Trials

Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients

Start date: August 26, 2018
Phase:
Study type: Observational

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with inflammatory bowel disease (IBD) in Saudi Arabia where no visits or intervention(s) additional to the daily practice will be performed.

NCT ID: NCT03077412 Completed - Clinical trials for Fistulizing Crohn's Disease

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Divergence2
Start date: April 6, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of filgotinib as compared to placebo in establishing combined fistula response at Week 24. Participants will have the option to enter a separate Long-Term Extension (LTE) study (GS-US-419-3896; NCT02914600) if they meet eligibility requirements.

NCT ID: NCT01624376 Completed - Clinical trials for Fistulizing Crohn's Disease

Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to investigate the safety and tolerability of locally administered DLX105 in treating enterocutaneous fistulas in Crohn's Disease patients. The study will consist of a screening period of approx. 2 weeks, a 4-week treatment period and a 2-week follow-up period. An end-of study visit is scheduled on Day 43, 2 weeks after the last study visit.